NeuroCores, Inc.
Company Details
Status: Private
Employees: 1-10
Location:
201 Washington St., #2600, Boston, MA 02108, US
Type:
sample
Technology:
sample
About: NeuroCores Inc. is a preclinical-stage biopharmaceutical company focused on developing treatments for rare pediatric neurological disorders and neurodegenerative diseases. The Company's lead product candidate, KIT-13, is undergoing nonclinical studies for Rett Syndrome and other neurodegenerative diseases, and it has been granted both Rare Pediatric Drug Designation and Orphan Drug Designation from the US FDA for treating Rett syndrome.
Additionally, NeuroCores has two more compounds, KIT-18 and KIT-20, for RCDP and Leigh Disease, respectively.
NeuroCores's innovative plasmalogen derivatives have the potential to treat many more CNS disorders because of their potent anti-neuroinflammatory and neurogenesis effects.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
NeuroCores, Inc. | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.